Thursday , July 29 2021

Glenmark Pharmaceuticals receives ANDA approval for Sirolimus tablets, 0.5 mg, 1 mg and 2 mg

Mumbai (Maharashtra) [India], Oct 19 (ANI/PRNewswire): Glenmark Pharmaceuticals Inc, USA (Glenmark) has received final approval by the United States Food & Drug Administration (US FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV.Mumbai (Maharashtra) [India], Oct 19 (ANI/PRNewswire): Glenmark Pharmaceuticals Inc, USA (Glenmark) has received final approval by the United States Food & Drug Administration (US FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV.Read More

About

Check Also

Post-IPO, promoter family of Nykaa to continue holding 51% stake

The company has followed an inventory-led model so that the authenticity of the quality of …

Leave a Reply

Your email address will not be published. Required fields are marked *